The Different Dose Of Atorvastatin Short-time Treatment On Serum Visfatin In Acute Coronary Syndrome Patients

Objective:(1)To observe the effects of atorvastatin on serum Visfatin and MMP-9, IL-6in Acute Coronary Syndrome patients,stable angina patients and health people.(2)To observe the effects of atorvastatin on serum visfatin and MMP-9, IL-6in Acute Coronary Syndrome patients, and discuss whether the application of different dose atorvastatin can be effective on anti-inflammation in the acute phase of ACS(Acute coronary syndrome).Method:(1) All patients with chest pain were randomly divided into two groups:40cases in Acute Coronary Syndrome group,20cases in Stable Angina group, meanwhile,20cases selected alternatively from outpatient without coronary heart disease as the control group.(2)40cases of Acute Coronary Syndrome patients within24hours after admission were randomly divided into two groups:one group was treated with atorvastatin (20mg/night), the other group was treated with atorvastatin (40mg/night), After10days treatment, the serum visfatin (Visfatin) and matrix metalloproteinase-9(MMP-9), interleukin (IL-6)(using ELISA method for detection) and serum lipid levels were detected.Results:(1)Serum visfatin levels in patients with acute coronary syndrome温were obviously increased than those in the control group and stable angina group(P<0.01); serum visfatin levels in patients with stable angina patients were also increased than those in the control group, but the difference was not statistically significant (P>0.05);(2) There were no difference in TC, TG, HDL-C and LDL-C level between routine Group and higher dosage Group before the treatment(P>0.05), After one month treatment, TC and LDL-C level in routine Group and higher dosage Group were both decreased significantly(P<0.05),the TC and LDL-C level in higher dosage Group was significantly decreased than those of routine Group (P<0.05).(3)There was no difference in visfatin and MMP-9, IL-6level between routine Group and higher dosage Group before the treatment (P>0.05), but the difference was significantly higher than Control Group (P<0.05). After one month treatment, visfatin and MMP-9, IL-6level in routine Group and higher dosage Group were decreased significantly(P<0.05), the visfatin and MMP-9, IL-6level of high dosage Group decreased more than those in routine Group (P<0.05), the difference between the two Groups was statistically significant (P<0.05).(4)The Two dosage of atorvastatin treatment on ACS patients do not has the adverse event such as muscle pain, rash and severe gastrointestinal discomfort. Two groups of patients with different dose of atorvastatin therapy after the detection of plasma transaminase and myocardial enzyme levels were no more than the normal upper limit of3times.Conclusions:(1)Serum visfatin level in patients with acute coronary syndrome was higher than those in control group and stable angina group, but serum visfatin level with stable angina patients was not higher than those in the control group; Serum MMP-9、IL-6level in patients with acute coronary syndrome was higher than those in control group and stable angina group, stable angina patients was also higher than those in the control group.(2)Atorvastatin can significantly decrease the level of Visfatin, MMP-9, IL-6, TC and LDL-C.(3) Within a short-time treatment, the higher dose of atorvastatin shows to be safe, reliable, and less adverse reaction.